Intuitive Surgical, Inc. (ISRG)
Intuitive Surgical (ISRG) Reports Q4 Earnings: What Key Metrics Have to Say (Revised)
Although the revenue and EPS for Intuitive Surgical (ISRG) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
More Upside For ISRG Stock?
Intuitive Surgical reported strong Q4 2025 outcomes with adjusted EPS of $2.53, exceeding estimates of $2.26 and increasing by 14.5% from Q4 2024's $2.21. Revenue reached $2.87 billion, a 19% increase year-over-year that surpassed the consensus of $2.75 billion, while full-year revenue hit $10.1 billion (+21%) coupled with adjusted EPS of $8.93.
Intuitive Surgical (ISRG) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Intuitive Surgical (ISRG) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Intuitive Surgical, Inc. (ISRG) Q4 2025 Earnings Call Transcript
Intuitive Surgical, Inc. (ISRG) Q4 2025 Earnings Call Transcript
Intuitive Surgical, Inc. (ISRG) Q4 Earnings Surpass Estimates
Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $2.53 per share, beating the Zacks Consensus Estimate of $2.25 per share. This compares to earnings of $2.21 per share a year ago.
Intuitive Surgical beats quarterly estimates on demand for surgical robots
Intuitive Surgical on Thursday beat Wall Street estimates for fourth-quarter profit and revenue on growing demand for its surgical robots used in minimally invasive procedures.
ISRG vs. MDT: Which MedTech Stock Is a Better Bet Now?
Intuitive Surgical's pure-play robotics focus, rising da Vinci 5 utilization and 85% recurring revenues tilt the risk-reward versus diversified Medtronic.
Intuitive Surgical Pre-Q4 Analysis: Buy, Hold or Sell ISRG Stock Now?
ISRG heads into Q4 earnings with 18% procedure growth and da Vinci 5 demand, but valuation and tariffs keep the earnings outlook uncertain.
Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results
ISRG posts strong preliminary Q4 and full-year 2025 revenue growth, but shares dip as investors weigh procedure trends, margins and outlook.
Intuitive Surgical: Buying The Dip On This Wide-Moat Compounder
Intuitive Surgical continues robust double-digit growth, with Q4 2025 revenues up 19% y/y and strong da Vinci 5 adoption. The firm's 2026 procedure growth guidance of 13–15% disappointed versus expectations, triggering a recent share sell-off despite operational strength. Elevated multiples reflect the company's market dominance, but tactical buying on dips remains warranted for long-term growth investors.
Brokers Suggest Investing in Intuitive Surgical (ISRG): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Intuitive Surgical (ISRG) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Intuitive Surgical (ISRG) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
